United States:
What The FDA's New Framework Means For Regenerative Therapies (Video)
04 December 2017
Holland & Knight
To print this article, all you need is to be registered or login on Mondaq.com.
To view the video click here.
RARECast
The FDA recently passed a new policy framework governing the
development and oversight of regenerative medicine. Attorney
Michael Werner discussed these new policies and what they mean for
the industry at large on an episode of RARECast.
Duration: 27:20
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
